Similar articles

• The Janeway lecture. Hodgkin's disease--finding the balance between cure and late effects.

  Donaldson SS, Hancock SL, Hoppe RT. Donaldson SS, et al. Cancer J Sci Am. 1999 Nov-Dec;5(6):325-33. Cancer J Sci Am. 1999. PMID: 10606471 Review.
• Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.

  Renner C, Bauer S, Sahin U, Jung W, van Lier R, Jacobs G, Held G, Pfreundschuh M. Renner C, et al. Blood. 1996 Apr 1;87(7):2930-7. Blood. 1996. PMID: 8639913
• Targeting cellular FLICE-like inhibitory protein as a novel approach to the treatment of Hodgkin's lymphoma.

  Dutton A, Burns AT, Young LS, Murray PG. Dutton A, et al. Expert Rev Anticancer Ther. 2006 Jun;6(6):911-9. doi: 10.1586/14737140.6.6.911. Expert Rev Anticancer Ther. 2006. PMID: 16761935 Review.
• Second cancers following pediatric Hodgkin's disease.

  Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS. Wolden SL, et al. J Clin Oncol. 1998 Feb;16(2):536-44. doi: 10.1200/JCO.1998.16.2.536. J Clin Oncol. 1998. PMID: 9469338
• Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.

  Horning SJ, Negrin RS, Chao JC, Long GD, Hoppe RT, Blume KG. Horning SJ, et al. J Clin Oncol. 1994 Dec;12(12):2552-8. doi: 10.1200/JCO.1994.12.12.2552. J Clin Oncol. 1994. PMID: 7989928 Clinical Trial.